孔光耀，男，生物诊疗中心科室主任

    2011年取得南开大学生物化学与分子生物学博士学位。2011-2016年在美国威斯康星大学麦迪逊分校McArdle Laboratory for Cancer Research实验室任博士后、副研究员。2016年底全职回国，现任生物诊疗中心副主任、西安交通大学教授、博士生导师。2016年入选西安交通大学“青年拔尖人才支持计划”A类。2017年入选西安交大医学部首批攀登人才计划，2019年获国家优秀青年科学基金项目。中国生理学会血液生理委员会委员、中国医药治疗管理协会细胞治疗质量控制与研究专业委员会委员、陕西省抗癌协会理事。西安交通大学学报（医学版）编委。

    近年来一直致力于白血病领域的研究，利用基因工程小鼠研究Ras诱导的骨髓增殖性肿瘤（包括慢性粒单核细胞白血病和幼年型粒单核细胞白血病）发生发展的分子机制、疾病动物模型的构建及其靶向治疗等，并取得了一系列的研究成果。共发表SCI论文40余篇，其中以第一作者或共同第一作者在The Journal of Clinical Investigation (IF=12.575), Leukemia (IF=12.104), Blood (IF=11.841), Science Advances (Science子刊), Journal of Biological Chemistry (IF=4.258)等杂志发表学术论文12篇。

研究领域：

   白血病致病机制研究

   造血干细胞研究

   白血病靶向治疗

   小鼠动物模型构建

   临床前动物模型构建

主持项目 

 国家自然科学基金青年项目 Notch信号通路在幼年型粒单核细胞白血病中细胞自主性和非细胞自主性作用的研究 2017.01-2019.12 18万 主持

国家自然科学基金面上项目 Runx1在慢性粒单核细胞白血病中的作用及其机制研究 2018.01-2021.12 50万 主持

国家自然科学基金优秀项目 骨髓异常增生/骨髓增殖性肿瘤 2020.01-2022.12 120万 主持

国家重点研发计划课题 跨器官通讯影响病理状态下造血稳态的作用和机理 2019.12-2024.11 344万 课题负责人

代表性论文：

 

1. Li J, Li R, Jiang W, Sun J, Li J, Guo Y, Zhu K, Zhang C,Kong G#, Li Z#. Splenic serum from portal hypertensive patients enhances liver stem cell proliferation and self-renewal via the IGF-II/ERK signaling pathway. Dig Liver Dis. 2020 (#corresponding author)

2. Zhang H, Zhang S, Zhang J, Zhou R, Nie Y, Ren S, Li J, Feng K, Ji F,Kong G#, Li Z#. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. Platelets. 2019 (#corresponding author)

3. Zhu K, Li J, Li J, Sun J, Guo Y, Tian H, Li L, Zhang C, Shi M,Kong G#, Li Z#. Ring1 promotes the transformation of hepatic progenitor cells into cancer stem cells through the Wnt/β-catenin signaling pathway. J Cell Biochem. 2019 (#corresponding author)

4. Sun J, Guo Y, Bie B, Zhu M, Tian H, Tian J, Li J, Yang Y, Ji F,Kong G#, Li Z#. Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway. J Cell Biochem. 2019 (#corresponding author)

5. You X, Wen Z, Chang YI, Ranheim EA, Zhou Y, Zhou L,Kong G#, Zhang J#. Systemic Notch downregulation promotes KrasG12D -induced myeloproliferative neoplasm. Br J Haematol. 2019 (#corresponding author)
6.Kong G*#, You X*, Wen Z, Chang YI, Qian S, Ranheim EA, Letson C, Zhang X, Zhou Y, Liu Y, Rajagopalan A, Zhang J, Stieglitz E, Loh M, Hofmann I, Yang D, Zhong X, Padron E, Zhou L, Pear WS, Zhang J.#. Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. Leukemia. 2019 (#corresponding author) (Impact factor=10.02)
7. Lu Z*, Hong CC*, Kong G*, Assumpção ALFV#, Ong IM, Bresnick EH, Zhang J, Pan X. Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. Cell Rep. 22(6):1545-1559. 2018(*equal contribution)

8.Li Y, Jiang W, Li ZZ, Zhang C, Huang C, Yang J,Kong GY#, Li ZF#. Repetitive restraint stress changes spleen immune cell subsets through glucocorticoid receptor or β-adrenergic receptor in a stage dependentmanner. Biochem Biophys Res Commun. 2018 (#corresponding author)  (Impact factor=2.559) 

9.Jiang W, Li Y, Sun J, Li L, Li JW, Zhang C, Huang C, Yang J,Kong GY#, Li ZF#.Spleen contributes to restraint stress induced changes in blood leukocytes distribution.Sci Rep. 2017(#corresponding author)(Impact factor=4.122) 

 10.Zhang J*,Kong G*, Rajagopalan A, Lu L, Song J, Hussaini M, Zhang X, Ranheim EA, Liu Y, Wang J, Gao X, Chang YI, Johnson KD, Zhou Y, Yang D, Bhatnagar B, Lucas DM, Bresnick EH, Zhong X, Padron E, Zhang J.p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.Blood.2017(*equal contribution)(Impact factor=11.841)

  11.Kong G, Chang YI, You X, Ranheim EA, Zhou Y, Burd CE, Zhang J. The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent.Leukemia.2016(Impact factor=12.104)

  12.Kong G*,Chang Y-I*, Damnernsawad A*, You X*, Du J, Ranheim E, Lee W, Ryu M, Zhou Y, Xing Y, Chang Q, Burd C, Zhang J. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.Leukemia.2016 (*equal contribution)(Impact factor=12.104)

  13.Johnson, K. D.*,Kong, G*, Gao, X., Chang, Y .-I., Hewitt, K. J., Sanalkumar, R., Sanalkumar, P., Ranheim, R. A., Dewey, C. N., Zhang, J., and Bresnick, E. H. Cis-regulatory Mechanisms Governing Stem and Progenitor Cell Transitions. Science Advances.Science Advances2015 (*equal contribution)

  14.Kong G,Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.The Journal of Clinical Investigation.2014(Impact factor=12.575)

  15.Wang J*,Kong G*, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J. NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.Blood.2013 (*equal contribution)(Impact factor=11.841) 

16. Kong G*, Du J*, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J. Notch1 mutations target Kras G12D CD8+ cells and contribute to their leukemogenic transformation.J Biol Chem.2013 (*equal contribution)(Impact factor=4.258) 

17.  Zhang W*,Kong G*, Zhang J, Wang T, Ye L, Zhang X. MiR-520b inhibits growth of hepatoma cells by targeting cyclin D1 and MEKK2.PLoS ONE, 2012 (*equal contribution)(Impact factor=3.057)

18.Kong G,Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated MicroRNA-29a by Hepatitis B Virus X Protein Enhances Hepatoma Cell Migration by Targeting PTEN in Cell Culture Model.PLoS ONE.2011(Impact factor=3.057)  

19.Kong G,Zhang J, Zhang S, Shan C, Ye L, Zhang X. Hepatitis B Virus x protein promotes proliferation of hepatoma cells via upregulation of MEKK2.Acta Pharmacologica Sinica, 2011.(Impact factor=3.166)

 

西安交通大学第二附属医院

生物诊断治疗国家地方联合工程研究中心

邮箱地址: konggy@xjtu.edu.cn

通讯地址:陕西省西安市西五路157号, 710004